Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
| Revenue (Most Recent Fiscal Year) | $4.05B |
| Net Income (Most Recent Fiscal Year) | $22.20M |
| PE Ratio (Current Year Earnings Estimate) | 14.36 |
| PE Ratio (Trailing 12 Months) | 13.25 |
| PEG Ratio (Long Term Growth Estimate) | 4.26 |
| Price to Sales Ratio (Trailing 12 Months) | 1.68 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.11 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 6.35 |
| Pre-Tax Margin (Trailing 12 Months) | 0.75% |
| Net Margin (Trailing 12 Months) | -0.66% |
| Return on Equity (Trailing 12 Months) | 15.19% |
| Return on Assets (Trailing 12 Months) | 6.93% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.43 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.16 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.78 |
| Inventory Turnover (Trailing 12 Months) | 8.67 |
| Book Value per Share (Most Recent Fiscal Quarter) | $65.15 |
| Earnings per Share (Most Recent Fiscal Quarter) | $2.34 |
| Earnings per Share (Most Recent Fiscal Year) | $10.32 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.65 |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 49.12M |
| Free Float | 48.48M |
| Market Capitalization | $6.76B |
| Average Volume (Last 20 Days) | 1.29M |
| Beta (Past 60 Months) | 1.50 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 98.91% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |